Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cathay Fortune Corp, also known as Hongshang Group, is a prominent private investment conglomerate based in Shanghai with a strategic focus on life sciences, natural resources, and financial services. The company is a major player in the biotechnology sector primarily through its significant equity stakes in GenScript Biotech and its subsidiary Legend Biotech, which developed the landmark CAR-T therapy Carvykti. Through these holdings, Cathay Fortune is integrated into the synthetic biology, cell therapy, and life science research service markets. Additionally, the group maintains a presence in healthcare delivery and medical device manufacturing via its interests in Chimin Health Management. For a life sciences analyst, Cathay Fortune represents a major source of institutional capital and strategic control within the global biotech and pharmaceutical manufacturing ecosystems.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cathay Fortune.